Product Code: 978-1-68038-930-2
Single-cell Analysis Market Growth & Trends
The global single-cell analysis market size is expected to reach USD 14.99 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 18.3% from 2023 to 2030. Technology advances, expanding applications in cancer research, and higher government funding for cell-based research are the main drivers of the market. In addition, the market is advancing as a result of the COVID-19 pandemic. For instance, in January 2021, according to the American Journal of Physiology, variations in the peripheral blood mononuclear cellular profiles of COVID-19-infected patients were examined by using single-cell analysis (SEA) through mass cytometry, which supplemented the industry growth.
Government agencies around the world have increased funding for vaccine development and production in response to the ongoing pandemic's economic and social costs, which has increased the use of SEA tools for COVID-19 research. In order to develop better prognostic and diagnostic indicators and establish suitable therapeutic approaches for people with serious disease presentation, it is essential to know the host immune response throughout pathogenicity. Therefore, the market is positively impacted by COVID-19 because single-cell analysis helps in the assessment of peripheral immune function in the disease and makes new contributions to the study of the disease's pathophysiology and treatment possibilities.
Single-cell technology aids in the molecular level examination of pathways and processes as well as the assessment of cellular heterogeneity. This technology is developing rapidly with uses in oncology, immunology, and other fields. Further, the development of sophisticated tools that make transcriptomic and proteomic processes simpler is boosting the use of SEA methods. Researchers are now able to comprehensively examine previously unstudied uncommon cell types owing to developments in scRNA sequencing (scRNAseq). The application of single-cell genomic/transcriptomic analysis in the biomedical area has been greatly expanded by the development of microfluidics technology. Furthermore, cell dissociation and tissue digestion have been adapted for a large range of microfluidic devices, which have increased the adoption of SEA technology and further boosted industry growth.
The rising investment flow in R&D in this space is reflected in the rising number of research publications. For instance, in April 2020, A USD 2 million funding round was headed by the venture capital firm i&i Biotech Fund for Sampling Human, a young life science technology startup that has created a diagnostic platform that uses genetically modified cells to examine other cells in their environment (i&i Bio). Further, R&D and business growth will all be advanced by the investment. Moreover, these expenditures indicate a better growth opportunity for this market because R&D efforts serve as the foundation for innovation. Additionally, scientists are analyzing geographic variability in gene expression profiles at the single-cell level, which is expected to increase the demand for consumables and equipment for analysis, thus propelling the industry's growth.
Single-cell Analysis Market Report Highlights
- By product, the consumables segment held the largest revenue share in 2021. The segment is anticipated to be driven by the extensive use of consumables in genetic research, exosome analysis, and RNA and DNA isolation
- Based on application, the cancer segment captured the largest revenue share in 2022. The segment is being driven by single-cell analysis, which has shown to be successful for earlier cancer diagnoses. These techniques make it simple to determine cell kinds, mutation rates, and growth settings
- In terms of workflow, the single cell isolation and library preparation segment held the largest revenue share in 2022. Increasing research using single-cell analysis is anticipated to boost the revenue growth
- Based on end-user, the academic and research laboratories segment held the largest revenue share in 2022. The widespread use of different SEA techniques in research settings has been influenced by a sizeable number of ongoing research projects at academic institutions that use SEA assays
- North America held the largest revenue share in 2022. This is mostly attributed to the occurrence of significant market participants and rising R&D spending and federal assistance
- Asia Pacific is expected to grow at the highest rate over the forecast period owing to factors such as the increasing prevalence of target diseases, growing aging population, and rising single cell technology adoption
Table of Contents
Chapter 1. Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.1.1 Segment Definitions
- 1.1.1.1 Product Segment
- 1.1.1.2 Workflow Segment
- 1.1.1.3 Application Segment
- 1.1.1.4 End Use Segment
- 1.2 Information Procurement
- 1.2.1 Market Formulation & Data Visualization
- 1.2.2 Data Validation & Publishing
- 1.3 Research Assumptions
- 1.4 Research Methodology
- 1.4.1 Purchased Database
- 1.4.2 Gvr's Internal Database
- 1.4.3 Secondary Sources
- 1.4.5 Primary Research
- 1.4.6 Details Of Primary Research
- 1.5 Information Or Data Analysis
- 1.5.1 Data Analysis Models
- 1.6 Market Formulation & Validation
- 1.7 Model Details
- 1.7.1 Commodity Flow Analysis
- 1.5.1.1 Approach 1: Commodity Flow Approach
- 1.8 List Of Secondary Sources
- 1.9 Global Market: Cagr Calculation
- 1.10 Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables &Trends
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Related/Ancillary Market Outlook
- 3.2 Market Dynamics
- 3.2.1 Market Driver Analysis
- 3.2.1.1 Expanding Application Scope
- 3.2.1.1.1 Disease Diagnosis
- 3.2.1.1.2 Drug Discovery & Development
- 3.2.1.2 Lucrative Growth Of Sequencing Technology
- 3.2.1.3 Technological Innovations In Single-Cell Analysis And Cell Isolation
- 3.2.1.4 Rising Incidence Of Cancer
- 3.2.2 Market Restraint Analysis
- 3.2.2.1 High Cost Of Instruments
- 3.2.2.2 Higher Penetration Of Conventional Mode Of Gene & Cell Analysis
- 3.3 Industry Analysis Tools
- 3.3.1.Porter's Five Forces Analysis
- 3.3.2 Pestel Analysis
- 3.3.3 Covid-19 Impact Analysis
Chapter 4. Product Segment Analysis
- 4.1 Single Cell Analysis Market: Product Movement Analysis
- 4.2 Consumables
- 4.2.1 Consumables Market, 2018 - 2030 (USD Million)
- 4.2.2 Reagents
- 4.2.2.1 Reagents Market, 2018 - 2030 (USD Million)
- 4.2.3 Assay Kits
- 4.2.3.1 Assay Kits Market, 2018 - 2030 (USD Million)
- 4.3 Instruments
- 4.3.1 Instruments Market, 2018 - 2030 (USD Million)
- 4.3.2 Microscopes
- 4.3.2.1 Microscopes Market, 2018 - 2030 (USD Million)
- 4.3.3 Hemocytometers
- 4.3.3.1 Hemocytometers Market, 2018 - 2030 (USD Million)
- 4.3.4 Flow Cytometers
- 4.3.4.1 Flow Cytometers Market, 2018 - 2030 (USD Million)
- 4.3.5 Next Generation Sequencing (Ngs) Systems
- 4.3.5.1 Next Generation Sequencing (Ngs) System Market, 2018 - 2030 (USD Million)
- 4.3.6 Polymerase Chain Reaction (Pcr) Instruments
- 4.3.6.1 Polymerase Chain Reaction (Pcr) Instruments Market, 2018 - 2030 (USD Million)
- 4.3.7 High Content Screening Systems
- 4.3.7.1 High Content Screening Systems Market, 2018 - 2030 (USD Million)
- 4.3.8 Cell Microarrays
- 4.3.8.1 Cell Microarrays Market, 2018 - 2030 (USD Million)
- 4.3.9 Automated Cell Counters
- 4.3.9.1 Automated Cell Counters Market, 2018 - 2030 (USD Million)
- 4.3.10 Single Live Cell Imaging
- 4.3.10.1 Single Live Cell Imaging Market, 2018 - 2030 (USD Million)
Chapter 5. Application Segment Analysis
- 5.1 Single Cell Analysis Market: Application Movement Analysis
- 5.2 Cancer
- 5.2.1 Cancer Market, 2018 - 2030 (USD Million)
- 5.3 Immunology
- 5.3.1 Immunology Market, 2018 - 2030 (USD Million)
- 5.4 Neurology
- 5.4.1 Neurology Market, 2018 - 2030 (USD Million)
- 5.5 Stem Cell
- 5.5.1 Stem Cell Market, 2018 - 2030 (USD Million)
- 5.6 Non-Invasive Prenatal Diagnosis
- 5.6.1 Non-Invasive Prenatal Diagnosis Market, 2018 - 2030 (USD Million)
- 5.7 In-Vitro Fertilization
- 5.7.1 In-Vitro Fertilization Market, 2018 - 2030 (USD Million)
- 5.8 Others
- 5.8.1 Other Applicatios Market, 2018 - 2030 (USD Million)
Chapter 6. Workflow Segment Analysis
- 6.1 Single Cell Analysis Market: Workflow Movement Analysis
- 6.2 Single Cell Isolation & Library Preparation
- 6.2.1 Single Cell Isolation & Library Preparation Market, 2018 - 2030 (USD Million)
- 6.3 Downstream Analysis
- 6.3.1 Downstream Analysis Market, 2018 - 2030 (USD Million)
- 6.4 Data Analysis
- 6.4.1 Single Cell Isolation & Library Preparation Market, 2018 - 2030 (USD Million)
Chapter 7. End-Use Segment Analysis
- 7.1 Single Cell Analysis Market: End-Use Movement Analysis
- 7.2 Academic And Research Laboratories
- 7.2.1 Academic & Research Laboratories Market, 2018 - 2030 (USD Million)
- 7.3 Biotechnology And Pharmaceutical Companies
- 7.3.1 Biotechnology And Pharmaceutical Companiesmarket, 2018 - 2030 (USD Million)
- 7.4 Hospitals And Diagnostic Laboratories
- 7.4.1 Hospitals And Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
- 7.5 Others
- 7.5.1 Other End-Uses, 2018 - 2030 (USD Million)
Chapter 8. Regional Business Analysis
- 8.1 Single Cell Analysis Market: Regional Movement Analysis
- 8.2 North America
- 8.2.1 North America Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.2.2 U.S.
- 8.2.2.1 U.S. Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.2.3 Canada
- 8.2.3.1 Canada Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3 Europe
- 8.3.1 Europe Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3.2 Uk
- 8.3.2.1 Uk Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3.3 Germany
- 8.3.3.1 Germany Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3.4 France
- 8.3.4.1 France Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3.5 Italy
- 8.3.5.1 Italy Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3.6 Spain
- 8.3.6.1 Spain Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3.7 Denmark
- 8.3.7.1 Denmark Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3.8 Sweden
- 8.3.8.1 Sweden Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.3.9 Norway
- 8.3.9.1 Norway Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.2 China
- 8.4.2.1 China Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.3 India
- 8.4.3.1 India Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.4 Japan
- 8.4.4.1 Japan Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.5 South Korea
- 8.4.5.1 South Korea Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.6 Australia
- 8.4.6.1 Australia Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.7 Thailand
- 8.4.7.1 Thailand Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.5 Latin America
- 8.5.1 Latin America Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.5.2 Brazil
- 8.5.2.1 Brazil Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.5.3 Mexico
- 8.5.3.1 Mexico Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.5.4 Argentina
- 8.5.4.1 Argentina Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.6 Middle East And Africa (Mea)
- 8.4.1 Mea Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.2 South Africa
- 8.4.2.1 South Africa Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.3 Saudi Arabia
- 8.4.3.1 Saudi Arabia Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.4 UAE
- 8.4.4.1 UAE Single-Cell Analysis Market, 2018 - 2030 (USD Million)
- 8.4.5 Kuwait
- 8.4.5.1 Kuwait Single-cell analysis market, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Share Analysis, 2022
- 9.4. Company Profiles/Listing
- 9.4.1. Illumina Inc
- 9.4.1.1. Overview
- 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. QIAGEN
- 9.4.2.1. Overview
- 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. Thermo Fisher Scientific, Inc.
- 9.4.3.1. Overview
- 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. Merck KGaA
- 9.4.4.1. Overview
- 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. Bio-Rad Laboratories, Inc.
- 9.4.5.1. Overview
- 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. BD
- 9.4.6.1. Overview
- 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Strategic Initiatives
- 9.4.7. Fluidigm
- 9.4.7.1. Overview
- 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. 10x Genomics, Inc.
- 9.4.8.1. Overview
- 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. BGI
- 9.4.9.1. Overview
- 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. Novogene Corporation
- 9.4.10.1. Overview
- 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Strategic Initiatives